Timothy J Roberts1,2, Andrew T Burns1,2, Richard J MacIsaac2,3, Andrew I MacIsaac1,2, David L Prior1,2, André La Gerche4,2,5,6. 1. Department of Cardiology, St Vincent's Hospital Melbourne, Fitzroy, Australia. 2. St Vincent's Department of Medicine, University of Melbourne, Fitzroy, Australia. 3. Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Australia. 4. Department of Cardiology, St Vincent's Hospital Melbourne, Fitzroy, Australia andre.legerche@baker.edu.au. 5. Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium. 6. Baker Heart and Diabetes Institute, Melbourne, Australia.
Abstract
OBJECTIVE: To determine whether pulmonary microvascular disease is detectable in subjects with diabetes and associated with diminished exercise capacity using a novel echocardiographic marker quantifying the pulmonary transit of agitated contrast bubbles (PTAC). RESEARCH DESIGN AND METHODS: Sixty participants (40 with diabetes and 20 control subjects) performed cardiopulmonary (maximal oxygen consumption [VO2peak]) and semisupine bicycle echocardiography exercise tests within a 1-week period. Pulmonary microvascular disease was assessed using PTAC (the number of bubbles traversing the pulmonary circulation to reach the left ventricle, categorized as low PTAC or high PTAC). Echocardiographic measures of cardiac output, pulmonary artery pressures, and biventricular function were obtained during exercise. RESULTS: Subjects with diabetes and control subjects were of similar age (44 ± 13 vs. 43 ± 13 years, P = 0.87) and sex composition (70% vs. 65% male, P = 0.7). At peak exercise, low PTAC was present in more participants with diabetes than control subjects (41% vs. 12.5%, χ2P = 0.041) and, in particular, in more subjects with diabetes with microvascular complications compared with both those without complications and control subjects (55% vs. 26% vs. 13%, χ2P = 0.02). When compared with high PTAC, low PTAC was associated with a 24% lower VO2peak (P = 0.006), reduced right ventricular function (P = 0.015), and greater pulmonary artery pressures during exercise (P = 0.02). CONCLUSIONS: PTAC is reduced in diabetes, particularly in the presence of microvascular pathology in other vascular beds, suggesting that it may be a meaningful indicator of pulmonary microvascular disease with important consequences for cardiovascular function and exercise capacity.
OBJECTIVE: To determine whether pulmonary microvascular disease is detectable in subjects with diabetes and associated with diminished exercise capacity using a novel echocardiographic marker quantifying the pulmonary transit of agitated contrast bubbles (PTAC). RESEARCH DESIGN AND METHODS: Sixty participants (40 with diabetes and 20 control subjects) performed cardiopulmonary (maximal oxygen consumption [VO2peak]) and semisupine bicycle echocardiography exercise tests within a 1-week period. Pulmonary microvascular disease was assessed using PTAC (the number of bubbles traversing the pulmonary circulation to reach the left ventricle, categorized as low PTAC or high PTAC). Echocardiographic measures of cardiac output, pulmonary artery pressures, and biventricular function were obtained during exercise. RESULTS: Subjects with diabetes and control subjects were of similar age (44 ± 13 vs. 43 ± 13 years, P = 0.87) and sex composition (70% vs. 65% male, P = 0.7). At peak exercise, low PTAC was present in more participants with diabetes than control subjects (41% vs. 12.5%, χ2P = 0.041) and, in particular, in more subjects with diabetes with microvascular complications compared with both those without complications and control subjects (55% vs. 26% vs. 13%, χ2P = 0.02). When compared with high PTAC, low PTAC was associated with a 24% lower VO2peak (P = 0.006), reduced right ventricular function (P = 0.015), and greater pulmonary artery pressures during exercise (P = 0.02). CONCLUSIONS:PTAC is reduced in diabetes, particularly in the presence of microvascular pathology in other vascular beds, suggesting that it may be a meaningful indicator of pulmonary microvascular disease with important consequences for cardiovascular function and exercise capacity.
Authors: Timothy J Roberts; Andrew T Burns; Richard J MacIsaac; Andrew I MacIsaac; David L Prior; André La Gerche Journal: J Appl Physiol (1985) Date: 2019-05-02
Authors: Isabel Boden; Miguel O Bernabeu; Baljean Dhillon; David A Dorward; Ian MacCormick; Roly Megaw; Claire Tochel Journal: Diabetes Res Clin Pract Date: 2022-04-05 Impact factor: 8.180
Authors: Vesa V Hyrylä; Antti-Pekka E Rissanen; Juha E Peltonen; Anne S Koponen; Heikki O Tikkanen; Mika P Tarvainen Journal: Front Physiol Date: 2022-02-18 Impact factor: 4.566